Showing results (851-860 of 5,837) with videos related to

Sort By:
Pageof 584
Drug Design, Development and Therapy|July 2, 2020
Suppression of Cisplatin-Induced Hepatic Injury in Rats Through Alarmin High-Mobility Group Box-1 Pathway by Ganoderma lucidum: Theoretical and Experimental StudyHanan M Hassan, Lamya H Al-Wahaibi, Mohammed A Elmorsy, et al.
Drug Design, Development and Therapy|July 2, 2020
Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivoGao-Fei Ren, Li-Li Xiao, Xiao-Jun Ma, et al.
Drug Design, Development and Therapy|July 2, 2020
Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and Helicobacter pylori InfectionSaeed Moayedi, Abbas Yadegar, Saeed Balalaie, et al.
Drug Design, Development and Therapy|July 2, 2020
Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivoHongzhang Wu, Xurui Cheng, Feiyan Huang, et al.
Drug Design, Development and Therapy|April 3, 2015
Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysisHui Shi, Tao Guo, Peng-Cheng Liu, et al.
Drug Design, Development and Therapy|April 3, 2015
In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged miceNadiah Abu, Nurul Elyani Mohamed, Swee Keong Yeap, et al.
Drug Design, Development and Therapy|April 3, 2015
Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cellsZhi-Wei Zhou, Xing-Xiao Li, Zhi-Xu He, et al.
Drug Design, Development and Therapy|April 3, 2015
The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cellsJin-Ping Li, Yin-Xue Yang, Qi-Lun Liu, et al.
Drug Design, Development and Therapy|April 3, 2015
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancerMitsukuni Suenaga, Nobuyuki Mizunuma, Satoshi Matsusaka, et al.
Drug Design, Development and Therapy|April 8, 2015
Modeling, molecular dynamics, and docking assessment of transcription factor rho: a potential drug target in Brucella melitensis 16MJangampalli Adi Pradeepkiran, Konidala Kranthi Kumar, Yellapu Nanda Kumar, et al.
Pageof 584